Hormonal
GLP-1 receptor agonists (GLP-1 RAs) reduce systemic and intestinal inflammation in Inflammatory Bowel Disease (IBD) by modulating immune cell signaling, enhancing the intestinal epithelial barrier, and improving gut microbiota composition.
If you have IBD and are considering GLP-1 medications (like Semaglutide or Liraglutide) for weight loss or diabetes, current evidence suggests they may actually help your gut health by reducing inflammation and lowering the risk of surgery. Start with a low dose and titrate slowly to manage nausea. Monitor your symptoms, but know that studies show these drugs do not increase the risk of IBD flares or hospitalizations compared to other diabetes medications. If you are underweight, discuss this carefully with your doctor, as the primary benefit in obese IBD patients is well-documented.
GLP-1 RAs appear to lessen the intestinal inflammatory burden by enhancing intestinal epithelial barrier features and modulating the gut microbiota. GLP-1 RAs protect cells from inflammatory damage by reducing oxidative stress and promoting tissue homeostasis through these mechanisms.
Why this rating
The paper is a narrative review citing strong preclinical data (animal models, in vitro) and retrospective human cohort studies, but lacks large-scale randomized controlled trials (RCTs) for IBD specifically.
Source
Relevance of Glucagon-Like Peptide 1 (GLP-1) in Inflammatory Bowel Diseases: A Narrative Review
Antonietta Gerarda Gravina et al. · Current Issues in Molecular Biology · 2025
DOI 10.3390/cimb47050383
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →